Highest-materiality recent filing
Standard BioTools Q1 revenue $21.1M, up 5% YoY; operating loss cut 54%
Net loss from continuing ops $14.6M vs $23.4M YoY; adjusted EBITDA loss $3.1M, 78% improvement.
Notice on April 20, 2026: common stock closed below $1.00 for 30 consecutive business days.
Standard BioTools Q4 rev $23.8M (-4% YoY); FY2025 rev $85.3M (-6%); guides FY2026 $80-85M
Q4 2025 net income from continuing ops $13.9M (includes $38.4M deferred tax release) vs net loss $27.2M YoY.
Standard BioTools completes sale of SomaScan business to Illumina for ~$363.7M net cash
Net cash proceeds of ~$363.7M from sale of SomaLogic and Sengenics entities to Illumina.
Standard BioTools completes SomaLogic sale to Illumina for up to $425M; holds ~$550M cash
Received $350M upfront cash at closing; eligible for up to $75M in earnout payments based on 2025-2026 revenue targets.
Standard BioTools prelim Q4 revenue ~$56M, FY2025 ~$185M; SomaLogic sale on track
Q4 combined rev ~$56M (continuing ops ~$24M); FY2025 combined ~$185M (continuing ~$85M).
Standard BioTools Q3 revenue $19.6M, net loss $31.7M; restructuring targets $40M savings
Revenue from continuing ops $19.6M, down 11% YoY; net loss $31.7M vs $21.9M loss in Q3 2024.
Standard BioTools cuts 15% of workforce, expects $7.5M in restructuring costs
Company commenced restructuring plan reducing global workforce by approx. 15%.
Standard BioTools to consolidate R&D to Singapore, reduce US workforce, expects $3.6M in costs
Consolidates South San Francisco R&D into Singapore facility to co-locate with manufacturing.
Standard BioTools Q2 revenue $21.8M, net loss improves; sells SomaLogic to Illumina for up to $425M
Q2 2025 continuing ops revenue $21.8M, down 3% YoY; net loss $17.7M vs $25.4M loss a year ago.
Standard BioTools grants 3M RSUs to CEO Egholm, 1.5M to CFO Kim; CFO bonus target raised to 80%
CEO Michael Egholm granted 3,000,000 RSUs; 25% vest Aug 1, 2026, then 25% annually over 3 years.
Standard BioTools sells SomaLogic to Illumina for up to $425M; expects $550M cash at close
Upfront cash payment of $350M at closing plus up to $75M in near-term earnout milestones for total up to $425M.
Standard BioTools Q1 2025 revenue $40.8M (-10% YoY); net loss $26.0M, adj EBITDA loss $16.9M
First-quarter revenue $40.8M, down 10% YoY; consumables -16%, instruments +24%, services -16%.
Standard BioTools reports Q4 pro forma revenue $46.7M, down 9% YoY; 2025 guidance $165-175M
Q4 pro forma revenue $46.7M (down 9% YoY); full year $175.1M (down 9% YoY).
Standard BioTools CCO Jeremy Davis to depart Feb 1, 2025; severance details disclosed
Jeremy Davis will step down as Chief Commercial Officer effective February 1, 2025, by mutual agreement.
Standard BioTools Q3 revenue $45M, net loss improves 34.6% YoY; reaffirms FY2024 outlook
Q3 2024 revenue $45.0M (-5% YoY pro forma); net loss $26.9M improved from $41.2M loss YoY.
Standard BioTools Q2 revenue $37.2M, net loss $45.7M; FY2024 guidance cut to $170-175M
Q2 revenue $37.2M (pro forma combined -23% YoY); net loss $45.7M; adjusted EBITDA loss $31.0M.
Madryn withdraws director nominations for Standard BioTools annual meeting
Madryn Asset Management affiliate irrevocably withdrew its March 15 notice to nominate directors and submit a business proposal at the 2024 annual meeting.
As-reported revenue $45.5M (+81% YoY from SomaLogic merger); pro forma combined revenue $46.2M (+2% YoY).
Standard BioTools cuts 10% of workforce, targets $45-50M annual savings in FY2025
Reduction-in-force of ~10% including senior management positions eliminated after SomaLogic merger.
Standard BioTools exchanges all Series B Preferred for ~93M common shares
Exchanged 127,780 Series B-1 and 127,779 Series B-2 shares for 92,930,553 common shares at $2.75 per share.
Standard BioTools FY2023 revenue $106M (+9%); Q4 gross margin 59.6%; SomaLogic merger closed
FY2023 revenue $106.3M (+9% YoY); Q4 revenue $28.2M (+4%); instrument sales +46% for FY.
On January 3, 2025, Standard BioTools Inc. (the “Company”) and Jeremy Davis, the Company’s Chief Commercial Officer, mutually determined that Mr. Davis will no longer serve in such position, effective as of February 1, 2025.
On November 6, 2024, the Board of Directors of Standard BioTools Inc. (the “Company”) appointed Alex Kim, who has been serving as the Company’s Interim Chief Financial Officer since September 1, 2024, as the Company’s fulltime Chief Financial Officer, effective as of November 11, 2024 (the “Effective Date”).
On July 26, 2024, Jeffrey Black resigned as the Senior Vice President and Chief Financial Officer (serving as the principal financial and accounting officer) of Standard BioTools Inc. (the “Company”), effective as of August 31, 2024.
On July 30, 2024, the Company’s Board of Directors appointed Alex Kim, the Company’s Chief Operating Officer, to serve as Interim Chief Financial Officer of the Company, starting on September 1, 2024, to succeed Mr. Black while the Company searches for a permanent Chief Financial Officer.
Max materiality 0.85 · Median 0.65 · Most common event earnings